The safety profile of vitamin D supplements using real-world data from 445,493 participants of the UK biobank: slightly higher hypercalcemia prevalence but neither increased risks of kidney stones nor atherosclerosis
Background: Potential calcium-related adverse events of vitamin D supplement use have not been addressed in large-scale, real-world data so far. Methods: Leveraging data from the UK Biobank, encompassing 445,493 individuals aged 40-69, we examined associations of high 25-hydroxyvitamin (25(OH)D) lev...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
12 July 2024
|
| In: |
Nutrients
Year: 2024, Volume: 16, Issue: 14, Pages: 1-17 |
| ISSN: | 2072-6643 |
| DOI: | 10.3390/nu16142251 |
| Online Access: | Verlag, kostenfrei, Volltext: https://doi.org/10.3390/nu16142251 Verlag, kostenfrei, Volltext: https://www.mdpi.com/2072-6643/16/14/2251 
|
| Author Notes: | Sha Sha, Miriam Degen, Tomislav Vlaski, Ziwen Fan, Hermann Brenner and Ben Schöttker |
| Summary: | Background: Potential calcium-related adverse events of vitamin D supplement use have not been addressed in large-scale, real-world data so far. Methods: Leveraging data from the UK Biobank, encompassing 445,493 individuals aged 40-69, we examined associations of high 25-hydroxyvitamin (25(OH)D) levels ≥ 100 nmol/L and vitamin D supplementation with hypercalcemia (serum calcium > 2.6 mmol/L), kidney stones, and atherosclerosis assessments (pulse wave arterial stiffness index and carotid intima-medial thickness). Regression models were comprehensively adjusted for 49 covariates. Results: Approximately 1.5% of the participants had high 25(OH)D levels, 4.3% regularly used vitamin D supplements, and 20.4% reported regular multivitamin use. At baseline, the hypercalcemia prevalence was 1.6%, and 1.1% was diagnosed with kidney stones during follow-up. High 25(OH)D levels were neither associated with calcium-related adverse events nor atherosclerosis assessments. Vitamin D and multivitamin supplementation were associated with an increased prevalence of hypercalcemia (odds ratios and 95% confidence intervals: 1.46 [1.32-1.62] and 1.11 [1.04-1.18], respectively) but were neither associated with atherosclerosis nor future kidney stones. Conclusions: High 25(OH)D levels observable in routine care were not associated with any adverse outcome. Vitamin D users have a slightly higher prevalence of hypercalcemia, possibly due to co-supplementation with calcium, but without a higher atherosclerosis prevalence or risk of kidney stones. |
|---|---|
| Item Description: | Gesehen am 15.01.2025 |
| Physical Description: | Online Resource |
| ISSN: | 2072-6643 |
| DOI: | 10.3390/nu16142251 |